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Purpose: The aim of this study was to evaluate prognostic impor-
tance of chromosomal instability (CIN) in non-small cell lung cancers 
(NSCLC). We examined the relationship between CIN detected by 
ﬂuorescence in situ hybridization and survival in patients with NSCLC 
and subgroup. 
Experimental Design: 132 surgical specimens of NSLC were studied. 
The patients included 109 men and 23 women, with an median age of 
59 years. Tumors included 64 adenocarcinomas (AC), 68 squamous 
cell carcinomas (SCC). The pathologic stage was IA in 22, IB in 53, 
IIA in 5, IIB in 28, IIIA in 18, and IIIB in 6 cases. Multi-target DNA 
FISH assay (LAVysion, Vysis) was used to determine which tumors 
carried CIN. Survival were compared according to the following fac-
tors: gender, age, histology, T factor, N factor, CIN and smoking status. 
Results: Fifty tumors (37.9%) showing numerical heterogeneity in 
all four examined chromosomes were judged to be carrying CIN. The 
percentage of CIN was signiﬁcantly higher in Adenocarcinoma group 
than squamous cell carcinoma group. (54.7% vs 22.1%, p < 0.001) 
The rate of lymph node involvement was lower in CIN positive group. 
(26% vs 43.9%, p = 0.039) The CIN positive group had lower smoking 
history. (26.0 ± 24.0 vs 35.1 ± 24.2, p = 0.036) In multivariate analysis, 
there was no signiﬁcant differences two groups. Kaplan-Meier survival 
curves according to CIN status shows no signiﬁcant differences. Log-
rank test revealed only gender factor predicted a poor survival.
Conclusions: Our study demonstrates that CIN is more frequent in AC 
than SCC. But CIN is not an independent prognostic factor in the group 
of patients with NSCLC and in the subgroups: both with AC and SCC. 
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Background: The prognosis of lung cancer is still poor, since there are 
few early detection tools available yet. So, it is important to identify 
more efﬁcient and clinically applicable biomarkers associated with the 
prognosis in as earlier stages as possible.
Method: In this study, we ﬁrstly observed the expression proﬁle of 
CD63 in 33 cases of non-small cell lung cancers (NSCLC) using real-
time quantitative RT-PCR. To explore the potential of this molecule as 
a prognostic biomarker for lung cancer subtypes, we constructed tissue 
microarrays with 90 NSCLCs. Then immunohistochemistry analysis 
was performed with anti-CD63 antibody. Signiﬁcance of the associa-
tion between CD63 expression status and clinicopathological param-
eters was tested by Chi-square test and two-sided Fisher’s exact test 
using SPSS version 12.0 and STATA version 7.0 software.
Result: Majority of NSCLCs (75.8%) showed lower CD63 RNA level 
(less than half) than normal tissue. Notably, all SqCs showed low-ex-
pression except one case, while AdCs showed diverse range of expres-
sion. CD63 protein expression level was largely compatible with RNA 
level. Totally, 63.3% of NSCLC were CD63 protein expression nega-
tive. All SqCs were negative, while majority (70.2%) of adenocarcino-
mas (AdCs) were positive. CD63 protein negativity was signiﬁcantly 
associated with SqCs type, larger tumor size, and advanced stage. In 
AdCs, CD63 negativity was associated with poor survival (p=0.008). 
This association was also signiﬁcant in earlier stage (I and II) AdCs 
(p=0.041), but not in advanced stage AdCs. After being adjusted for 
age and sex by Cox regression and stratiﬁed by stages, CD63 negativity 
still showed borderline association with poor survival as an indepen-
dent predictor (p=0.076, HR=2.3).
Conclusion: Taken together, these results suggest that CD63 can be a 
biomarker for predicting the prognosis in earlier stage of lung AdCs. 
Our ﬁndings can be a clue to investigate the role of CD63 in tumori-
genesis of AdCs of lung and other cancers.
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Background: Lung cancer is the biggest cause of cancer death in the 
US and Europe. Recently an increased understanding of the molecu-
lar biology of Non-small cell lung cancer (NSCLC) has led to the 
introduction of novel targeted therapies. The epidermal growth factor 
(EGFR), commonly overexpressed in NSCLC has emerged as an at-
tractive target. This has led to the development of the EGFR tyrosine 
kinase inhibitors (TKIs) erlotinib and geﬁtinib and the monoclonal 
antibody directed against the EGFR, cetuximab. Other agents targeting 
the EGFR are in various stages of development. Several studies have 
shown that patients with somatic mutations in the EGFR TK domain 
are more sensitive to TKIs while mutations in K-ras, a mediator of 
EGFR signalling, are associated with resistance. Overexpression of the 
EGFR, detected by immunohistochemistry does not predict response 
to anti-EGFR therapy. Determining gene copy of the EGFR using 
ﬂuorescent in situ hybridisation (FISH) appears to predict response to 
the TKI’s. Determining gene copy number of the EGFR using RT-PCR 
technology is not well explored and the prognostic value of this is as 
yet unknown. 
Aim: The natural history of these mutations is unknown therefore the 
aim of this study is to examine a cohort of 200 patients who underwent 
resection for NSCLC, between 2002-2004 in St. James’Hospital, for 
EGFR/K-ras mutational status and EGFR ampliﬁcation and expression. 
Methods: DNA is extracted from the parafﬁn-embedded tumour tis-
sue of each patient. Exons 19 and 21 of the EGFR gene and exon 2 of 
the K-ras gene are ampliﬁed using nested PCR. The PCR product is 
bidirectionally sequenced using BigDye Terminator v3.1 on the ABI 
3100 sequencing instrument. The DNA is also subjected to quantita-
